Premium
Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report
Author(s) -
Vogelmeier Claus F.,
Criner Gerard J.,
Martinez Fernando J.,
Anzueto Antonio,
Barnes Peter J.,
Bourbeau Jean,
Celli Bartolome R.,
Chen Rongchang,
Decramer Marc,
Fabbri Leonardo M.,
Frith Peter,
Halpin David M.G.,
López Varela M. Victorina,
Nishimura Masaharu,
Roche Nicolas,
RodriguezRoisin Roberto,
Sin Don D.,
Singh Dave,
Stockley Robert,
Vestbo Jørgen,
Wedzicha Jadwiga A.,
Agusti Alvar
Publication year - 2017
Publication title -
respirology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.857
H-Index - 85
eISSN - 1440-1843
pISSN - 1323-7799
DOI - 10.1111/resp.13012
Subject(s) - medicine , copd , obstructive lung disease , pulmonary disease , intensive care medicine , disease , lung disease , lung , physical therapy
ABSTRACT This Executive Summary of the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD ) 2017 Report focuses primarily on the revised and novel parts of the document. The most significant changes include: (i) the assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation. ABCD groups are now proposed to be derived exclusively from patient symptoms and their history of exacerbations; (ii) for each of the groups A to D, escalation strategies for pharmacological treatments are proposed; (iii) the concept of de‐escalation of therapy is introduced in the treatment assessment scheme; (iv)non‐pharmacological therapies are comprehensively presented and (v) the importance of co‐morbid conditions in managing COPD is reviewed.